(19)
(11) EP 2 275 087 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.11.2012 Bulletin 2012/47

(45) Mention of the grant of the patent:
05.09.2012 Bulletin 2012/36

(21) Application number: 10154259.5

(22) Date of filing: 22.02.2010
(51) International Patent Classification (IPC): 
A61K 9/16(2006.01)
A61K 31/4365(2006.01)
 A61K 9/20(2006.01)

(54)

Prasugrel controlled release formulations

Formulierungen mit gesteuerter Freisetzung von Prasugrel

Formulations de libération contrôlée de prasugrel

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(43) Date of publication of application:
19.01.2011 Bulletin 2011/03

(73) Proprietor: JRS Pharma GmbH & Co. KG
73494 Rosenberg (DE)

(72) Inventor:
  • Dr. Glänzer, Klaus
    22337, Hamburg (DE)

(74) Representative: Becker Kurig Straus 
Bavariastrasse 7
80336 München
80336 München (DE)


(56) References cited: : 
EP-A1- 2 360 159
US-A1- 2007 243 243
 WO-A2-2004/098713
US-A1- 2009 281 136
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).